Alprostadil (Caverject/MUSE) Cost in Montana 2026

What Does Alprostadil Cost in Montana Right Now?

Retail cash-pay prices for branded alprostadil in Montana average approximately $600 per month in 2026, whether you choose Caverject (intracavernosal injection) or MUSE (intraurethral suppository). Generic injectable alprostadil is available and can reduce that figure, though pharmacy-to-pharmacy variation across Billings, Missoula, Great Falls, and rural Montana is meaningful. Calling ahead to compare prices at independent and chain pharmacies is worth the five minutes.

The landmark trial establishing alprostadil's efficacy, Linet et al. (N=296, NEJM 1996), showed that intracavernosal alprostadil produced a satisfactory erection in 94% of injections versus 11% with placebo [1]. That clinical track record explains why the drug remains a preferred second-line agent after oral PDE5 inhibitors fail, and why demand stays steady despite the price.

Cost breakdown by product category in Montana:

• Caverject (Pfizer, branded): approximately $580 to $640 per package at Montana retail pharmacies [2]
• Generic injectable alprostadil: approximately $300 to $420 per package depending on the supplier and dispensing pharmacy
• MUSE urethral suppository (branded): approximately $580 to $620 per box of 6 suppositories [2]
• Compounded alprostadil (503A pharmacy): $0 to $150 per month depending on the compounding pharmacy and whether a telehealth membership fee applies

The FDA's approved labeling for Caverject confirms the recommended starting dose of 2.5 mcg intracavernosal, titrated upward based on response, with a ceiling of 60 mcg per injection and no more than three injections per week [3].

Does Montana Medicaid Cover Alprostadil?

Montana Medicaid does not cover alprostadil for erectile dysfunction as of 2026. This is consistent with federal Medicaid guidance that explicitly excludes drugs used for treatment of sexual or erectile dysfunction from mandatory coverage unless a separate clinical indication exists, per 42 U.S.C. § 1396r-8(d)(2) [4].

Coverage exclusions apply specifically to Caverject, MUSE, and their generics when the listed diagnosis is erectile dysfunction. A patient with a documented neurogenic or vasculogenic cause secondary to a covered condition (spinal cord injury, for example) may be able to appeal through Montana's prior authorization process, though approval is not guaranteed. The Montana Department of Public Health and Human Services administers these appeals, and written documentation from a urologist carries more weight than a general practitioner note alone [5].

Patients enrolled in Montana's Children's Health Insurance Program (CHIP) are not eligible for this medication by age criteria, and that program follows similar federal exclusions [4].

Is Compounded Alprostadil Legal in Montana?

Yes. Compounded alprostadil is legal in Montana when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber [6]. Section 503A of the Federal Food, Drug, and Cosmetic Act permits traditional pharmacy compounding for individual patients when specific conditions are met, including a valid prescription and use of approved bulk drug substances [6].

Montana's Board of Pharmacy licenses and inspects resident compounding pharmacies. Out-of-state 503A pharmacies may also ship to Montana patients provided they hold a non-resident pharmacy license issued by the Montana Board of Pharmacy and comply with Montana Administrative Rules Title 24, Chapter 174 [7].

Compounded alprostadil is often formulated as a trimix or bimix combination (alprostadil plus papaverine, with or without phentolamine) that can lower per-dose costs substantially below branded Caverject pricing. Some telehealth platforms serving Montana patients work directly with 503A pharmacies and include medication cost in a monthly membership, which can bring effective out-of-pocket cost to near zero for the drug itself [8].

One practical note: 503B outsourcing facilities, which produce larger batches without patient-specific prescriptions, operate under different FDA oversight. Compounded alprostadil from a 503B facility requires specific FDA guidance permitting its compounding; patients should confirm their pharmacy's licensing tier before ordering [6].

Which Insurance Plans Cover Alprostadil in Montana?

Coverage varies widely. The short answer: commercial insurance in Montana may cover alprostadil, but many plans exclude erectile dysfunction drugs by policy exclusion or require step therapy through oral PDE5 inhibitors first [9].

Key coverage pathways for Montana residents:

Employer-sponsored plans. Many large employer plans operating under ERISA are self-insured and set their own formularies. Pfizer's patient assistance and savings card programs apply to commercially insured patients, potentially reducing Caverject out-of-pocket cost to as low as $0 per fill for eligible patients [10].

ACA marketplace plans. Montana marketplace plans sold through HealthCare.gov are not required to cover erectile dysfunction medications. Formulary placement differs by plan tier. Reviewing the Summary of Benefits and Coverage document for each plan before enrollment is the only reliable way to confirm alprostadil coverage.

Medicare Part D. Federal law prohibits Part D coverage of drugs used for treatment of sexual or erectile dysfunction under 42 U.S.C. § 1395w-102(e)(2)(A) [11]. Alprostadil for ED is excluded from Medicare Part D coverage in Montana just as in every other state.

VA benefits. Veterans receiving care through the VA Montana Health Care System in Fort Harrison may have alprostadil covered under VA formulary when erectile dysfunction is service-connected or linked to a covered condition such as diabetes or spinal cord injury [12].

A 2020 analysis in the Journal of Sexual Medicine found that only 38% of commercially insured men with an ED diagnosis successfully obtained insurance coverage for any prescription ED therapy on the first submission, with prior authorization denial rates exceeding 40% for injectable alprostadil specifically [13].

How to Get the Lowest Alprostadil Price in Montana

Several concrete strategies reduce cost.

GoodRx and pharmacy discount programs. GoodRx coupons for generic injectable alprostadil at Montana pharmacies have shown prices as low as $285 to $340 per package, depending on dose and quantity. Prices fluctuate; checking GoodRx or RxSaver before each fill takes under two minutes and can save over $100 per fill.

Pfizer Patient Assistance Program. Pfizer's RxPathways program offers Caverject at no cost to uninsured or underinsured patients who meet income eligibility criteria. Enrollment requires a physician attestation form and proof of income [10].

Pfizer Caverject Savings Card. Commercially insured patients who are not enrolled in any federal or state government health program may use Pfizer's savings card to reduce co-pays. The card is not valid for Medicare, Medicaid, or CHIP beneficiaries [10].

Compounded alprostadil via telehealth. Licensed telehealth platforms that operate in Montana can connect patients with prescribers and 503A pharmacies. Monthly membership fees typically range from $75 to $199 and often include the compounded medication. This route bypasses retail pharmacy pricing entirely.

Mail-order pharmacies. A 90-day supply ordered through a mail-order pharmacy affiliated with your insurance plan can reduce per-unit cost by 15% to 30% compared with a 30-day retail fill, for plans that do cover alprostadil.

The table below summarizes the cost tiers a Montana patient is likely to encounter in 2026:

| Route | Estimated Monthly Cost (MT, 2026) | |---|---| | Branded Caverject or MUSE, cash pay | ~$600 | | Generic injectable alprostadil, cash pay | ~$300 to $420 | | Branded + Pfizer savings card (commercially insured) | $0 to $50 co-pay | | Compounded alprostadil, 503A pharmacy + telehealth | $0 to $199 (membership model) | | Montana Medicaid | Not covered | | Medicare Part D | Not covered |

Can Montana Patients Get Alprostadil via Telehealth?

Yes. Montana permits telehealth prescribing of alprostadil. The Montana Telehealth Act (Mont. Code Ann. § 33-22-138) requires that telehealth services meet the same standard of care as in-person services, and the state does not impose a specific in-person visit requirement before a prescriber can issue a prescription for alprostadil [14].

Prescribers must hold an active Montana medical license or qualify under the Montana Enhanced Nurse Practitioner Practice Act for advanced practice providers. The prescriber-patient relationship can be established via synchronous audio-video consultation, which is the standard used by most telehealth ED platforms [14].

From a clinical safety standpoint, a 2019 review in Translational Andrology and Urology noted that proper patient training on self-injection technique is essential to minimize priapism risk, which occurred at a rate of approximately 1% in clinical trials of intracavernosal alprostadil [15]. Telehealth platforms typically provide instructional video modules and require patients to perform a supervised first injection (in-person or via video) before self-administering at home.

The AUA's 2018 guideline on erectile dysfunction states: "Patients who have not had an adequate trial of PDE5 inhibitors or have contraindications should be offered intracavernosal injection therapy as a second-line option" [16]. Telehealth prescribers in Montana follow this same clinical hierarchy.

Clinical Background: Why Alprostadil Is Prescribed

Alprostadil is a synthetic prostaglandin E1 (PGE1) analog. It relaxes smooth muscle in the corpus cavernosum by stimulating adenylate cyclase and increasing intracellular cyclic AMP, which triggers vasodilation and tumescence independent of the nitric oxide pathway used by PDE5 inhibitors [17]. That mechanism makes alprostadil effective in patients who cannot tolerate or do not respond to sildenafil, tadalafil, or vardenafil.

FDA approval for Caverject dates to 1995 and for MUSE to 1996 [3]. The key MUSE trial (Williams et al., N=1,511) found that 64.9% of men using alprostadil urethral suppository had at least one successful intercourse attempt during the 3-month study period versus 18.6% with placebo [18]. Intracavernosal delivery typically produces higher response rates than intraurethral delivery, though the injection route carries a greater procedural burden.

Contraindications include hypersensitivity to alprostadil, conditions predisposing to priapism (sickle cell anemia, multiple myeloma, leukemia), penile anatomical deformity, and concomitant use of other vasoactive agents for erectile dysfunction [3]. Patients on anticoagulants require additional monitoring when using intracavernosal injections because of bleeding risk at the injection site [17].

Side effects reported in clinical trials include penile pain (in approximately 37% of patients using Caverject), prolonged erection (>4 hours, in approximately 4%), and urethral burning (in approximately 32% of MUSE users) [1][3].

Alprostadil Dosing and Administration in Brief

Starting dose for Caverject in patients without neurogenic etiology is 2.5 mcg, injected into the corpus cavernosum. The prescriber or clinical team titrates upward in 2.5 to 5 mcg increments until a response adequate for intercourse is achieved without exceeding 60 mcg or a duration of more than 1 hour [3]. Patients with neurogenic etiology (spinal cord injury, for example) start at 1.25 mcg due to heightened sensitivity [3].

MUSE starting doses are 125 mcg or 250 mcg intraurethral, titrated to 500 mcg or 1 to 000 mcg based on clinical response [3]. Patients should urinate before insertion to provide a moist urethral surface that facilitates suppository absorption.

The FDA label specifies no more than two MUSE doses in a 24-hour period and no more than three Caverject injections per week, with at least 24 hours between injections [3]. These limits reduce the risk of fibrosis at the injection site, a complication documented in approximately 3% of long-term users in the Linet et al. trial [1].

Montana-Specific Resources for Alprostadil Patients

Montana has 56 counties, and pharmacy access in rural areas (the Hi-Line corridor, for example) is limited. Mail-order and telehealth options are especially relevant for patients in Havre, Lewistown, Wolf Point, and similar communities where the nearest compounding pharmacy may be 100 or more miles away.

The Montana Primary Care Association operates federally qualified health centers (FQHCs) across the state that provide sliding-scale fee services [19]. FQHCs may access the 340B Drug Pricing Program, which can reduce the cost of FDA-approved drugs including generic alprostadil by 25% to 50% for eligible low-income patients [20].

Montana also participates in the Partnership for Prescription Assistance (now folded into Medicine Assistance Tool at needymeds.org), which aggregates manufacturer patient assistance programs. Patients with incomes at or below 400% of the federal poverty level may qualify for Pfizer's patient assistance program for Caverject [10].